Access to health

At LEO Pharma, we focus on patient engagement to increase our impact on patients by enhancing our ability to meet patients’ unmet need in our products. We seek to leverage patient insights systematically, bringing the patient voice into our business from early scouting, development and launch. As such, our work evolves around integration, involvement, support, and communication. By understanding and integrating the daily realities of patients, we ensure that decisions - from disease focus over treatment development to building general awareness of unmet need in medical dermatology - create lasting value for patients, healthcare professionals, and society. We measure and tracks patient engagement across key functions, providing clear direction on how to collaborate with patients in developing treatments. Furthermore, we continue to support patient communities and networks, whether it being through grants or project-based collaborations. At present, LEO Pharma provides grants to Global Parents for Eczema Research, International Alliance of Dermatological Patient Organizations/Global Skin and International Federation of Psoriasis Associations/IFPA, in addition to local patient organizations across countries where we are present with direct operations.

The aspiration is for this approach to enable LEO Pharma to advance care standards, reduce stigma, and make a meaningful impact on the lives of those who need it most. In addition to our work with patient engagement, we continuously interact with healthcare professionals and healthcare organizations who provide us with valuable, independent and expert knowledge from their experience within the therapeutic focus area of LEO Pharma.

From skin conditions to critical care, we help supply relief to millions. This commitment extends to our global donations program, where we, through our long-term, multi-year partnership with International Health Partners (IHP), donate critically needed health products to people in crises across the world. For over a decade, we have partnered closely to ensure the delivery of our medicines to areas and patients in dire need. Our structured donation process is a multi-stakeholder effort, executed twice annually, involving collaboration between LEO Pharma, IHP and its local partner organizations. Since 2013, our response to emergencies has included donations of more than 414,500 units of medical products that have provided essential relief during critical situations through 26 shipments to 29 countries, reaching approximately 540,000 patients¹⁵. Each donation is carefully validated to ensure product quality, alignment with local needs and compliance with ethical and regulatory standards, reinforcing our commitment to global health and meeting the unmet need.

LEO Pharma has the expertise and global reach to take innovation from lab to worldwide impact. Today, we leverage our global footprint and deep expertise in skin biology and critical care to serve close to 100 million patients worldwide¹⁶. We are proud of our global footprint with a presence in more than 70 markets worldwide, ensuring relief for both developed and developing countries. An overview of our direct operations globally is always available at https://www.leo-pharma.com/#global-picker.

Forming partnerships allows us to utilize our expertise to collaboratively drive innovation and broaden our portfolio. More than half of our markets are Alliance Markets, where we partner with trusted local organizations to promote, distribute and in some countries manufacture our products. We have a close collaboration with our partners to ensure that standards in Quality and Pharmacovigilance are upheld. Furthermore, we collaborate with local manufacturers in range of countries, including developing countries, either as contract manufacturers or license manufacturers. In both instances, our collaboration seeks to improve capacity and access to medicine that follows Good Manufacturing Practices. We ensure continuous dialogue and support on technical and quality matters with all partners.

Our network of partners is mainly spread across four regions, i.e. South-east Asia, Latin America, Middle East & North Africa, and Central Europe. These partnerships allow us to extend our reach and ensure we can make a meaningful difference in the lives of patients worldwide, across both developed and developing countries. Our partners and distributors have unique local expertise and understanding of patient needs, as well as interacting with doctors and providers in their respective markets.

In addition to our commercial partnerships, our ambition is also to serve as a vital integrator within the dermatology innovation ecosystem. By leveraging our deep disease insights and skin biology expertise, we seek to define problems and collaborate with partners to develop effective treatments. We partner with academia, biotech, pharma, investors, patient organizations, and contract research organizations to strengthen our portfolio, improving patient care and treatment pathways for various skin diseases. Together, we combine our expertise and resources, enabling us to make meaningful advancements.

Through external partnerships we are able to strengthen our portfolio in our pursuit to help more patients, better and faster. Together with healthcare leaders, scientific partners and patient groups, we will make a lasting impact in, on and far beyond the skin.

The prices of LEO Pharma medicines reflect the value our medicines bring to patients and to society as a whole. We assess the value of our treatments holistically, considering clinical outcomes, quality of life improvements, and economic benefits for patients, caregivers, and society. Our aim is to price our products in a transparent way, based on the value of medicine, local market conditions, and economic factors.

LEO Pharma provides pricing data for all countries when required by local health authorities and does not discriminate between developed or developing countries. LEO Pharma complies with all International Reference Pricing activities and is, as such, subject to price differences between countries which are based on several factors including but not limited to affordability.

The LEO Pharma pricing policy is applicable to all LEO Pharma products.

LEO Pharma recognizes the balance between ensuring that patients have access to affordable medicines and supporting the development of innovative new medicines on commercially sustainable terms. We support all regulatory and payer requirements related to generic competition.

We acknowledge antimicrobial resistance (AMR) as a public health risk theme. As a company, LEO Pharma is committed to minimizing AMR from occurring or further growing. While we are not actively conducting R&D to address antibiotic resistance, our anti-inflammatory treatments of skin disorders lower the need for antibiotics due to significant reductions in infection risks – and thereby indirectly contributing to the fight against AMR.

We recognize that prolonged use of topical antibiotics may contribute to resistance and should only be used when there is confirmed or suspected bacterial infection. To mitigate this risk, we emphasize the importance enforcing its use for short courses of 7-14 days, unless dosage guidelines state a longer course is needed and always in accordance with label, with suitable intervals between treatments. This approach supports our commitment to responsible antibiotic stewardship and minimizing the development of resistance.